Skip to main content
OpenTrials
Completed

NCT Number: NCT04181606

Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion

This study will test the central hypothesis that postmenopausal women will demonstrate increased oxygen extraction in active leg muscle during leg cycling exercise while receiving an infusion of Esmolol, a fast-acting β1 selective antagonist, when compared to premenopausal women

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

Noll Laboratory

University Park, Pennsylvania, 16803, United States

About this study

This study will test the central hypothesis that postmenopausal women will demonstrate increased oxygen extraction in active leg muscle during leg cycling exercise while receiving an infusion of Esmolol, a fast-acting β1 selective antagonist, when compared to premenopausal women. β1 selective antagonists (or "β1 blockers") are used to lower heart rate and improve O2 supply-to-demand balance in patients with coronary artery disease. By using esmolol to attenuate the central sympathetic response to exercise (increased heart rate and cardiac output) we can examine peripheral mechanisms of O2 delivery. The current project will evaluate how older postmenopausal women adjust active muscle O2 supply to an acute reduction in systemic O2 delivery during large muscle dynamic exercise when compared to younger premenopausal women.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

3.1 Inclusion Criteria

  • Capable of giving informed consent
  • Premenopausal women ages 18-35 years OR post-menopausal women ages 55-70 years
  • Satisfactory medical history and physical exam, as determined by a Clinical Research Center (CRC) clinician
  • Not currently taking medications affecting heart rate or contractility
  • Fluent in written and spoken English

3.2 Exclusion Criteria

Participants who will not be studied are those who:

  • Are less than 19 years of age or more than 70 years of age
  • Are pregnant or lactating
  • Are prisoners or institutionalized individuals or unable to consent
  • Diagnosed renal failure (Creatinine >2.0 mg/dl)
  • Diagnosed liver disease (ALT and aspartate aminotransferase {AST} 2 times normal)
  • Diagnosed Reynaud's disease
  • Have uncontrolled diabetes
  • Have uncontrolled hypertension
  • Have a left ventricular ejection fraction < 40%
  • Have a recent history of unstable angina or myocardial infarction (<6 months), unstable angina, or use of nitrate medications within past 2 weeks
  • Severe lung disease (i.e., on supplemental oxygen or frequently use rescue inhalers) 11. Diagnosed bleeding or clotting disorder or recent blood transfusion 12. Have asthma, history of thyroid issues or hyperkalemia 13. Known use of recreational drugs 14. Methylphenidate use

Treatment and study plan

Esmolol infusion

Drug

The Esmolol loading dose will be 0.5 mg/kg fat free mass/min administered over the first 3 minutes, followed by a maintenance dose of 0.25 mg/kg fat free mass/min for the remainder of the protocol (maximum of 60 minutes).

Other names: Esmolol Hydrochloride

Saline infusion

Drug

Saline will be rate/volume matched to the calculated esmolol dose.

Other names: Normal saline solution

Pre exercise baseline

Other

Subject rests quietly while drug infusion begins (3 min loading dose followed by 10 min of maintenance dose) until heart rate and blood pressure stabilize.

Isometric handgrip exercise

Other

The subject will grip at 40% of their maximum and maintain that grip for 90 seconds. Once at rest and once during heavy intensity cycling.

Semi-recumbent cycling

Other

Subjects will pedal for 2-4 minutes at a very light intensity (20W), followed immediately by 5 minutes at a moderate intensity (at a workload intended to elicit 85% of the oxygen consumption observed at the lactate threshold), and 5 minutes of cycling at a heavy intensity (at a workload estimated to elicit oxygen consumption half way between those observed at the lactate threshold and respiratory compensation point). Subjects will then continue cycling at the heavy intensity for 90 seconds while performing isometric handgrip exercise.

Primary outcomes

  1. Tissue Saturation Index (TSI) - Active Leg Muscle

    Time frame: Last 60 seconds of Rest, Moderate exercise, and Heavy Exercise.

    The primary outcome variable is the change in skeletal muscle oxygenation (∆TSI%) in the active leg muscle from baseline during recumbent cycling using near-infrared spectroscopy. TSI% represent the percentage of oxygenated hemoglobin relative to total hemoglobin in the tissue beneath the NIRS probe. Lower values represent a greater reduction in tissue oxygenation from baseline (greater oxygen extraction and/or reduced oxygen delivery).

    TSI% = oxy[heme] / total[heme] x 100

Secondary outcomes

  1. Tissue Saturation Index - Inactive Forearm Muscle

    Time frame: Last 60 seconds of Rest, Moderate exercise, and Heavy Exercise.

    The change in skeletal muscle oxygenation (∆TSI%) in the inactive forearm from baseline during recumbent cycling using near-infrared spectroscopy. TSI% represent the percentage of oxygenated hemoglobin relative to total hemoglobin in the tissue beneath the NIRS probe. Lower values represent a greater reduction in tissue oxygenation from baseline (greater oxygen extraction and/or reduced oxygen delivery).

    TSI% = oxy[heme] / total[heme] x 100

  2. Systolic Blood Pressure

    Time frame: At rest and 3 minutes into moderate exercise and heavy exercise.

    Systolic Blood Pressure recorded via an automatic sphygmomanometer (SunTech Tango)

  3. Heart Rate

    Time frame: Last 60 seconds of Rest, Moderate exercise, and Heavy Exercise.

    Heart rate recorded via EKG

  4. Cardiac Output

    Time frame: Last 60 seconds of Rest, Moderate exercise, and Heavy Exercise.

    Cardiac Output recorded using bioimpedance cardiography

  5. Diastolic Blood Pressure

    Time frame: At rest and 3 minutes into moderate exercise and heavy exercise.

    Diastolic Blood Pressure recorded via an automatic sphygmomanometer (SunTech Tango)

  6. Mean Arterial Pressure

    Time frame: At rest and 3 minutes into moderate exercise and heavy exercise.

    Mean Arterial Pressure recorded via an automatic sphygmomanometer (SunTech Tango)

  7. Stroke Volume

    Time frame: Last 60 seconds of Rest, Moderate exercise, and Heavy Exercise.

    Stroke Volume recorded using bioimpedance cardiography

  8. Systemic Vascular Conductance

    Time frame: Last 60 seconds of Rest, Moderate exercise, and Heavy Exercise.

    Systemic Vascular Conductance recorded using bioimpedance cardiography

  9. ∆HHb - Inactive Forearm

    Time frame: Last 60 seconds of Moderate and Heavy Exercise

    Change in deoxygenated hemoglobin (∆HHb) in the inactive forearm muscle from baseline during recumbent cycling exercise using near-infrared spectroscopy (NIRS) relative to the Total Labile Signal.

    ∆HHb is an index of oxygen extraction obtained using NIRS. The total labile signal is defined as the difference between the highest observed HHb value during 5 minutes of limb occlusion at 250 mmHg and the lowest observed HHb value observed during reperfusion following removal of the occlusion.

    Greater ∆HHb values indicate greater oxygen extraction in the tissue under the NIRS probe.

Sponsors and collaborators

Lead sponsor

David N. Proctor, PhD

Other

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Nov 29, 2019
Registry last updated
May 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.